Skip to main content
profile image for
  • Assistant Professor, Patient Oriented Research, Feinstein Institutes for Medical Research
  • Assistant Professor, Medicine and Pediatrics, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

About the investigator

After completing medical school and residency, Dr. Sherry Farzan returned to Long Island, where she grew up, to pursue training in allergy and immunology. As a fellow, she noticed how her patients with asthma would respond differently to the same medications. She was also intrigued by the co-burgeoning epidemics of asthma and obesity. She has therefore sought out to clarify the relationship between asthma and obesity, and is studying the role of different medications, which may be more effective in the obese asthmatic. She has completed a randomized trial to evaluate if montelukast may be a more effective controller medication than the first line inhaled corticosteroids in obese asthmatics. Currently she is recruiting for a study to assess the molecular basis of differences in medication response in obese versus lean asthmatics.

Research focus

Asthma and obesity

Differential medication responses in obese versus lean asthmatics, molecular basis of asthma in the obese, and the role of vitamin D in chronic urticaria.


Harvard Medical School
Degree: MD

Yale University
Degree: BA


  1. Farzan S, Khan S, Elera E, Akerman M. “Montelukast is a Better Controller in Obese Atopic Asthmatics.” Journal of Clinical Allergy and Immunology, 137 (2): AB210 (Abstract), 2016
  2. Diaz J, Farzan S. “Clinical Implications of the Obese Asthma Phenotypes.” North American Clinics of Allergy and Immunology. 34 (2014): 739-51
  3. Farzan, S. “The Asthma Phenotype in the Obese: Distinct or Otherwise?” J Allergy 2013, Article ID 602908, 8 pages, 2013.